

24th November 2015

## ASX ANNOUNCEMENT

### RESULTS OF ANNUAL GENERAL MEETING

Analytica Limited (ASX: ALT) advises that all resolutions were passed by a show of hands.

Proxy votes received were as follows:

Resolution	For	Open votes (Chairman nominated as proxy)	Total Votes For the resolution	Against
1. Remuneration report	76,866,769 72.35%	16,443,330 15.48%	<b>93,310,099</b> <b>87.83%</b>	12,937,462 12.17%
2. Re-election of Dr Michael Monsour	339,894,681	10,164,863	<b>350,059,544</b>	13,143,227
3. Election of Dr Thomas Lönngren	340,493,545	10,166,049	<b>350,659,594</b>	12,643,177
4. Ratification of Top Up Placement	149,418,144	12,210,703	<b>161,628,847</b>	20,598,489
5. Ratification of previous issue of options	320,229,405	11,273,293	<b>331,502,698</b>	14,489,920
6. Grant of options to Dr Thomas Lönngren	315,733,273	9,427,293	<b>325,160,566</b>	38,530,405
7. Grant of options to Mr Carl Stubbings	312,744,463	9,418,103	<b>322,162,566</b>	38,130,405
8. Special Resolution - Approval of Enhanced Placement Capacity	317,573,418 91.80%	11,272,793 3.26%	<b>328,846,211</b> <b>95.06%</b>	17,108,199 4.94%
9. Special Resolution Adoption of New Constitution	318,648,984 92.12%	17,471,159 5.05%	<b>336,120,143</b> <b>97.17%</b>	9,770,825 2.83%

*About Analytica Limited*

*Analytica's lead product is the PeriCoach™ System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.*

*PeriCoach™ comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is correctly performing pelvic floor exercises and if these are improving her condition; otherwise physicians are guided on the need for surgery.*

*PeriCoach™ has been approved in Australia with product launches expected in 2014 in Australia, and Europe and the US in 2015. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence. The product is not available for sale in the USA.*

*Analytica is also commercialising the AutoStart™ Infusion System. This is a burette with improved safety and cost reduction features. It is targeting a \$3 billion pa global market, has FDA approval and potential near term cash flow with distribution agreements.*